HAT worked in a consulting or advisory role for Array BioPharma, Bristol Myers Squibb (BMS), Genentech/Roche, Merck, and Novartis; participated in a scientific advisory board for Kayopharm; received research or grant support from BMS, Celgene, Genentech/Roche, GlaxoSmithKline, and Merck; and received honoraria from Eisai. ZE has worked on advisory boards for Pfizer, Array, OncoSec, Regeneron, Genentech, Novartis, Eisai, and Natera, and has received research funding from Novartis, Pfizer, and Boehringer-Ingelheim. CKA has received research funding from PUMA, Lilly, Merck, Seattle Genetics, Nektar, Tesaro, G1-Therapeutics, ZION, Novartis, and Pfizer; has compensated consultant roles with Genentech, AstraZeneca, Eisai, Elucida, and IPSEN; has previously had compensated consultant roles with Seattle Genetics, Novartis, Immunomedics, and Athenex; has received royalties from UpToDate and Jones and Bartlet. KAM worked in a consulting or advisory role for ImaginAb, Oncosec, Werewolf, Xilio, and Tentarix; participated in a Data Safety Monitoring board for CheckMate Pharmaceuticals; and received research or grant support from ImaginAb.